Extra MSA

Extra MSA
Name	Extra MSA
Specialty	Neurology

Extra MSA is a proposed nosological entity described in specialist literature as a multisystem neurodegenerative syndrome with prominent extracerebral manifestations. It has been discussed in relation to established disorders such as Parkinson's disease, Multiple system atrophy, Progressive supranuclear palsy, Lewy body dementia and Corticobasal degeneration, and debated at meetings of organizations like the European Academy of Neurology and the American Academy of Neurology. Clinicians and researchers reference institutions including Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, UCL Queen Square Institute of Neurology and journals such as The Lancet Neurology and Brain when characterizing its features.

Definition and Scope

Extra MSA denotes a spectrum of syndromes in which hallmark features traditionally attributed to Multiple system atrophy are accompanied or dominated by prominent peripheral, autonomic, or non-neurological involvement. The term has been used by investigators from centers including Charité – Universitätsmedizin Berlin, Karolinska Institutet, Centre Hospitalier Universitaire de Bordeaux and McGill University to delineate cases that overlap with entities managed at clinics such as Cleveland Clinic and reviewed at conferences like the World Congress of Neurology. Debates comparing this construct with classifications from the World Health Organization and diagnostic criteria from the Movement Disorder Society frame its scope.

Clinical Presentation

Patients described under this rubric present with combinations of parkinsonism, cerebellar signs, autonomic failure and prominent peripheral features. Case series from Stanford University School of Medicine and Columbia University Irving Medical Center document symptoms including orthostatic hypotension, urinary incontinence, erectile dysfunction, peripheral neuropathy and respiratory dysfunction alongside bradykinesia, rigidity and ataxia. Extrapyramidal signs are contrasted with findings in cohorts studied at University College London and University of Toronto, while non-motor manifestations attract attention from specialists affiliated with National Institutes of Health and Mount Sinai Hospital. Reports in journals such as Neurology and Annals of Neurology emphasize variability akin to syndromes described by researchers at Mayo Clinic and Johns Hopkins Hospital.

Diagnosis and Differential Diagnosis

Diagnosis is clinicopathological and relies on integration of neurological examination, neuroimaging, autonomic testing and, when available, neuropathology. Imaging modalities championed by teams at Massachusetts General Hospital and Karolinska Institutet include MRI, diffusion-weighted imaging and PET studies differentiating patterns seen in Multiple system atrophy, Parkinson's disease and Progressive supranuclear palsy. Autonomic laboratories at Cleveland Clinic and University of Washington perform tilt-table testing, urodynamics and sudomotor assessments to distinguish causes such as diabetic neuropathy investigated at Joslin Diabetes Center and paraneoplastic syndromes evaluated at Memorial Sloan Kettering Cancer Center. Differential considerations often involve entities tackled by specialists from Oxford University Hospitals and Hopkins including Lewy body dementia, Amyotrophic lateral sclerosis, Guillain–Barré syndrome and hereditary ataxias described at University of California, San Francisco.

Pathophysiology and Etiology

Pathophysiological models draw on neuropathological studies from centers like Mayo Clinic and University of Pennsylvania Perelman School of Medicine showing glial cytoplasmic inclusions, synucleinopathy, neuronal loss and gliosis in regions overlapping with those affected in Multiple system atrophy and Parkinson's disease. Proposed mechanisms incorporate alpha-synuclein aggregation described by researchers at Riken and RIKEN Center for Brain Science, prion-like propagation models discussed by teams at University of Cambridge and mitochondrial dysfunction investigated at Max Planck Institute for Biology of Ageing. Etiologic hypotheses include sporadic degeneration, environmental exposures reviewed by investigators at Imperial College London and genetic susceptibilities explored at Broad Institute and Wellcome Sanger Institute, with occasional reference to familial pedigrees reported from University of Helsinki.

Management and Treatment

Management strategies align with multidisciplinary care models practiced at Mayo Clinic, Cleveland Clinic and King's College Hospital. Symptomatic pharmacotherapy includes dopaminergic agents, autonomic-supportive measures and symptomatic relief guided by protocols from Harvard Medical School and Johns Hopkins Medicine. Nonpharmacological interventions such as physiotherapy, speech and swallow therapy and respiratory support are implemented by teams at Royal National Hospital for Neurology and Neurosurgery and Sunnybrook Health Sciences Centre. Advanced interventions—deep brain stimulation as studied at University of Florida, experimental immunotherapies trialed at National Institutes of Health and disease-modifying trials coordinated through networks including the European Reference Network—have limited or investigational roles. Palliative care integration as advocated by National Hospice and Palliative Care Organization and chronic care models from Veterans Health Administration are often necessary.

Prognosis and Complications

Prognosis is typically progressive with variable survival similar to cohorts followed at Mayo Clinic and Johns Hopkins Hospital. Major complications reported in longitudinal studies at University of California, San Diego and University of Melbourne include aspiration pneumonia, severe orthostatic hypotension, urinary tract infections, pressure ulcers and respiratory failure. Cognitive decline and neuropsychiatric symptoms resembling those described in Dementia with Lewy bodies cohorts at King's College London may occur. End-stage care pathways referenced by specialists at Mount Sinai Hospital emphasize advance care planning coordinated with services such as Meals on Wheels in community settings.

Epidemiology and Risk Factors

Epidemiological data are limited; prevalence estimates derive from registries and population studies conducted in regions served by Scandinavian centers, UK National Health Service databases and cohorts from Australia and Canada. Risk factors under investigation include older age, male sex, environmental exposures studied by teams at University of Exeter and University of California, Berkeley, and genetic variants identified in genomewide studies at Broad Institute and Wellcome Sanger Institute. Collaborative registries involving European Academy of Neurology, American Academy of Neurology and national rare disease networks aim to refine incidence and prevalence figures.

Category:Neurological disorders